News stories about Innospec (NASDAQ:IOSP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Innospec earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the specialty chemicals company an impact score of 45.179028452073 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Form DEFA14A INNOSPEC INC. (streetinsider.com)
- Zacks: Brokerages Anticipate Innospec Inc. (IOSP) to Post $0.98 EPS (americanbankingnews.com)
- BRIEF-Innospec Says CEO Patrick Williams’ FY 2017 Total Compensation Was $7.4 Mln Vs $6.8 Mln (reuters.com)
- Innospec Inc. (IOSP) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Innospec from a “sell” rating to a “hold” rating in a research note on Thursday, March 8th. ValuEngine upgraded shares of Innospec from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research lowered shares of Innospec from a “hold” rating to a “strong sell” rating in a research note on Friday, February 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $70.50.
Innospec (NASDAQ:IOSP) last issued its quarterly earnings results on Tuesday, February 13th. The specialty chemicals company reported $1.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.34. Innospec had a net margin of 4.73% and a return on equity of 15.57%. The business had revenue of $353.80 million for the quarter. research analysts predict that Innospec will post 4.3 EPS for the current year.
In other news, insider Philip Curran sold 1,268 shares of the business’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $68.24, for a total transaction of $86,528.32. Following the transaction, the insider now directly owns 2,998 shares in the company, valued at $204,583.52. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Philip John Boon sold 501 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $67.04, for a total transaction of $33,587.04. Following the transaction, the vice president now owns 35,439 shares in the company, valued at $2,375,830.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,112 shares of company stock worth $832,724. Company insiders own 2.02% of the company’s stock.
Innospec Company Profile
Innospec Inc is a specialty chemicals company engaged in developing, manufacturing, blending, marketing and supplying of specialty chemicals for use as fuel additives and ingredients for personal care, home care, agrochemical, mining and other applications and oilfield chemicals. The Company operates through four business segments: Fuel Specialties, Performance Chemicals, Oilfield Services and Octane Additives.
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.